Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SHINGRIX (GlaxoSmithKline Australia Pty Ltd)
Product name
SHINGRIX
Date registered
Evaluation commenced
Decision date
Approval time
91 (255 working days)
Active ingredients
recombinant Varicella Zoster Virus glycoprotein E antigen
Registration type
EOI
Indication
SHINGRIX (powder and suspension for injection) is now also indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia use in adults 18 years of age or older at increased risk of HZ.